These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 25519701)

  • 21. A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance.
    Berkers J; Govaere O; Wolter P; Beuselinck B; Schöffski P; van Kempen LC; Albersen M; Van den Oord J; Roskams T; Swinnen J; Joniau S; Van Poppel H; Lerut E
    J Urol; 2013 May; 189(5):1930-8. PubMed ID: 23206420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
    Beuselinck B; Job S; Becht E; Karadimou A; Verkarre V; Couchy G; Giraldo N; Rioux-Leclercq N; Molinié V; Sibony M; Elaidi R; Teghom C; Patard JJ; Méjean A; Fridman WH; Sautès-Fridman C; de Reyniès A; Oudard S; Zucman-Rossi J
    Clin Cancer Res; 2015 Mar; 21(6):1329-39. PubMed ID: 25583177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
    Zhou L; Liu XD; Sun M; Zhang X; German P; Bai S; Ding Z; Tannir N; Wood CG; Matin SF; Karam JA; Tamboli P; Sircar K; Rao P; Rankin EB; Laird DA; Hoang AG; Walker CL; Giaccia AJ; Jonasch E
    Oncogene; 2016 May; 35(21):2687-97. PubMed ID: 26364599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines.
    Pénzváltó Z; Tegze B; Szász AM; Sztupinszki Z; Likó I; Szendrői A; Schäfer R; Győrffy B
    PLoS One; 2013; 8(3):e59503. PubMed ID: 23555683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas.
    Mikami S; Mizuno R; Kosaka T; Saya H; Oya M; Okada Y
    Int J Cancer; 2015 Apr; 136(7):1504-14. PubMed ID: 25123505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma.
    Hwang HS; Go H; Park JM; Yoon SY; Lee JL; Jeong SU; Cho YM
    Lab Invest; 2019 May; 99(5):659-670. PubMed ID: 30683903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
    Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
    Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
    [No Abstract]   [Full Text] [Related]  

  • 28. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
    Sakai I; Miyake H; Fujisawa M
    BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics.
    Wang Y; Liu X; Gong L; Ding W; Hao W; Peng Y; Zhang J; Cai W; Gao Y
    Br J Pharmacol; 2023 Dec; 180(23):2937-2955. PubMed ID: 37740648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.
    Hillman GG; Singh-Gupta V; Zhang H; Al-Bashir AK; Katkuri Y; Li M; Yunker CK; Patel AD; Abrams J; Haacke EM
    Neoplasia; 2009 Sep; 11(9):910-20. PubMed ID: 19724685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma.
    Raphael J; Thawer A; Bjarnason GA
    Urol Oncol; 2018 Jan; 36(1):12.e1-12.e6. PubMed ID: 28966072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells.
    Zhu Y; Xu L; Zhang J; Hu X; Liu Y; Yin H; Lv T; Zhang H; Liu L; An H; Liu H; Xu J; Lin Z
    Cancer Sci; 2013 Aug; 104(8):1052-61. PubMed ID: 23578198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects.
    Kamli H; Owens EP; Vesey DA; Prasanna R; Li L; Gobe GC; Morais C
    Biochem Biophys Res Commun; 2022 Jan; 586():42-48. PubMed ID: 34826699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.
    Wang X; Zhang L; O'Neill A; Bahamon B; Alsop DC; Mier JW; Goldberg SN; Signoretti S; Atkins MB; Wood CG; Bhatt RS
    Br J Cancer; 2013 Feb; 108(2):319-26. PubMed ID: 23322198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
    Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
    Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-β pathway.
    Wang H; Zhang L; Liu H; Yang Y; Lu W; Cao X; Yang X; Qin Q; Song R; Feng D; Wang S; Bai T; He J
    Br J Cancer; 2024 Jul; 131(2):347-360. PubMed ID: 38822145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preoperative neoadjuvant targeted therapy remodels intra-tumoral heterogeneity of clear-cell renal cell carcinoma and ferroptosis inhibition induces resistance progression.
    Chen WJ; Pan XW; Song X; Liu ZC; Xu D; Chen JX; Dong KQ; Di SC; Ye JQ; Gan SS; Wang LH; Zhou W; Cui XG
    Cancer Lett; 2024 Jul; 593():216963. PubMed ID: 38768682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma.
    Grépin R; Ambrosetti D; Marsaud A; Gastaud L; Amiel J; Pedeutour F; Pagès G
    PLoS One; 2014; 9(3):e89449. PubMed ID: 24676409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.